The RAVE trial: Rituximab for ANCA-associated vasculitis [Classics Series]
Image: PD 1. Rituximab is non-inferior to cyclophosphamide in inducing remission of severe ANCA-associated vasculitis. 2. There were no significant ...
Image: PD 1. Rituximab is non-inferior to cyclophosphamide in inducing remission of severe ANCA-associated vasculitis. 2. There were no significant ...
Monthly plan selected: $4.99 /month.
5-day free trial · cancel anytime
Then $4.99/month. Manage renewal in your account.
Yearly plan selected: $49.90 /year.
2 months free · only $4.16/month
Then $49.90/year. Manage renewal in your account.
Already a member? Sign in
